ALF202 vs BGC101

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: No discrete molecular target · full Atherosclerotic Cardiovascular Disease pipeline

ALF202

Developed by Allife Medical Science and Technology

Phase 1 in Atherosclerotic Cardiovascular Diseasecell therapy (iPSC-derived endothelial progenitor cells)
Weak signal

NCT06359912 · Phase 1 · status unknown

This is a randomized study with a standard-of-care control group, but it is not blinded, enrolls a small number of patients, and its primary focus is safety rather than a disease-specific efficacy outcome; no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

BGC101

Developed by BioGenCell

Phase 1/2 in Atherosclerotic Cardiovascular Diseasecell therapy (autologous endothelial progenitor cells)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALF202BGC101
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

ALF202
—Not reported
BGC101
—Not reported

Non-HDL-C, % change

ALF202
—Not reported
BGC101
—Not reported

ApoB, % change

ALF202
—Not reported
BGC101
—Not reported

Lp(a), % change

ALF202
—Not reported
BGC101
—Not reported

3-point MACE (% with event)

ALF202
—Not reported
BGC101
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALF202: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

BGC101: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALF202's landscape · BGC101's landscape